載入...
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
The goal of anticancer therapy is to selectively eradicate all malignant cells. Unfortunately for the majority of patients with metastatic disease, this goal is consistently thwarted by the nearly inevitable development of therapeutic resistance; the main driver of therapeutic resistance is a minori...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5955127/ https://ncbi.nlm.nih.gov/pubmed/29805745 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25211 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|